Please assess the completion status of the following clinical trial:

Trial Title: An Evaluation of Glycemic Control Effects of Mono Therapy CKD-501 in Patients With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type Ⅱ diabetes mellitus~* Between 18 years and 80 years old~* The patient who has been taking oral hypoglycemic agent since 3 months with HbA1c 6.5 to 9% at screening test or who is drug naive or stopped taking oral hypoglycemic agent more then 3 months with HbA1c 7 to 10% at screening test~* BMI between 21kg/㎡ and 40kg/㎡~* Diagnosis of type Ⅱ diabetes before 3 months~* C-peptide level is over 1.0 ng/ml~* Condition for female having contraception methods, surgical sterilization or menopause~* Condition for male agreeing to use of recommendatory and appropriate contraception method~* Agreement with written informed consent~Exclusion Criteria:~* Type I diabetes, gestational diabetes or secondary diabetes~* Treatment with insulin or thiazolidinediones within 60 days~* Fasting Plasma Glucose level is over 250 mg/dl~* Triglyceride level is 500 mg/dl and over~* Uncontrollable hypertension(Although treat with antihypertension agent, systolic blood pressure greater than 140 mmHg and diastolic blood pressure greater than 90 mmHg)~* History of myocardial infarction, heart failure, cerebral infarction, hematencephalon or unstable angina within 6 months~* Severe hepatic dysfunction: AST, ALT, Total bilirubin, ALP level over or equal to 2.5 times as high as upper normal limit(UNL)~* Severe renal dysfunction: Renal failure or serum creatinine greater than 30% normal limit~* Anemia for any reason~* Needs treatment for acute disease, uncontrolled other diseae or diabetic complications~* Abnormality of thyroid function(out of normal TSH range )~* History of proliferative diabetic retinopathy~* In treatment concomitant drug having severe risk drug interaction with investigational drug~* History of cancer within 5 years~* History of drug abuse or alcoholism~* Hepatitis B Antigen(HBsAg) test is positive~* Treatment systemic or inhalant corticosteroids within 1 month prior to Screening~* Patient who have experience such as hypersensitivity reaction, serious adverse event or no effect by treatment with glitazones~* Fertile women who not practice contraception with appropriate methods~* Pregnant women or nursing mothers~* Has a contraindication to treatment investigational drug from the medical and psychogenic side~* An impossible one who participates in clinical trial by legal or investigator's decision~* Participated in other trial within 4 weeks~* Participating in other trial at present

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- CKD-501 0.5mg (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).